Recent Updates in The Role of Immunotherapies in Early NSCLC: Translating Evidence to Clinical Practice : Episode 4
Perioperative Treatment in Early-Stage NSCLC: AEGEAN Study
David Harpole, MD, discusses study design, results and clinical implications of the AEGEAN study of perioperative immunotherapy (neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in the treatment of early-stage NSCLC
EP: 1.Overview of Early-Stage NSCLC and Molecular Testing
EP: 2.Selecting Optimal Treatment in Early-Stage NSCLC
EP: 3.Neoadjuvant Therapy in Early-Stage NSCLC: CheckMate-816 Study
Now Viewing
EP: 4.Perioperative Treatment in Early-Stage NSCLC: AEGEAN Study
EP: 5.Perioperative Treatment in Early NSCLC: KEYNOTE-671 and NEOTORCH Studies
EP: 6.Neoadjuvant Versus Perioperative Therapy in Resectable NSCLC
EP: 7.Neoadjuvant Versus Adjuvant Therapy in Resectable NSCLC
EP: 8.Adjuvant Therapy in NSCLC: IMPower-010 and KEYNOTE-091 Studies
EP: 9.Treatment Strategy in Patients with Unresectable Stage I-III NSCLC
EP: 10.Consolidation Immunotherapy in Unresectable Early NSCLC: PACIFIC Study
EP: 11.Consolidation Immunotherapy in Unresectable Early NSCLC: Novel Approaches
EP: 12.Treatment for Patients Unsuitable for or Refractory to Consolidation Durvalumab
EP: 13.Practice Pearls for Community Oncologists Treating Early-Stage NSCLC
Related Videos
Related Content
